HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sugarbaker, D. J. Articles by Weissman, L. Search for Related Content PubMed PubMed Citation Articles by Sugarbaker, D. J. Articles by Weissman, L.

The Journal of Thoracic and Cardiovascular Surgery, Vol 102, 10-14, Copyright © 1991 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma

DJ Sugarbaker, EC Heher, TH Lee, G Couper, S Mentzer, JM Corson, JJ Collins Jr, R Shemin, R Pugatch and L Weissman
Division of Thoracic Surgery, Brigham & Women's Hospital, Boston, MA 02115.

Malignant pleural mesothelioma has been considered a uniformly fatal disease associated with a median survival of 4 to 18 months. Extrapleural pneumonectomy alone has proved disappointing in the treatment of this disease, as have chemotherapy and radiotherapy. From 1980 to 1990, 31 patients with pleural mesothelioma underwent multimodality therapy that included extrapleural pneumonectomy with resection of the pericardium and diaphragm. The age of the patients was 53.4 +/- 8.6 years; 26 were male. All patients had the pathologic diagnosis reviewed before treatment. At thoracotomy six patients had residual (unresectable) gross disease, and in 23 there was histologic evidence of disease at the resection margin. The perioperative morbidity and mortality rates were 19% and 6%, respectively. The mean length of hospital stay for the 29 patients who survived the operation was 10.9 +/- 3.5 days. Postoperatively 26 patients received cyclophosphamide, doxorubicin, and cis-platinum chemotherapy with or without radiotherapy. The survival rates were 70% at 1 year and 48% at 2 years. Trends toward improved survival in the patients with complete resections approached but did not reach statistical significance. These data suggest that this multimodality protocol can be administered with acceptable morbidity and mortality. Prospective trials are justified to further clarify the role of this approach.

This article has been cited by other articles:

				C. Aigner, M. A. R. Hoda, G. Lang, S. Taghavi, G. Marta, and W. Klepetko Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 204 - 207. [Abstract] [Full Text] [PDF]

				J. G. Edwards, A. E. Martin-Ucar, D. J. Stewart, and D. A. Waller Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy?: Short- and long-term results Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 759 - 764. [Abstract] [Full Text] [PDF]

				A. E. Martin-Ucar, D. J. Stewart, K. J. West, and D. A. Waller A Median Sternotomy Approach to Right Extrapleural Pneumonectomy for Mesothelioma Ann. Thorac. Surg., September 1, 2005; 80(3): 1143 - 1145. [Abstract] [Full Text] [PDF]

				A. Cesario, A. Catassi, L. Festi, A. Imperatori, A. Pericelli, D. Galetta, S. Margaritora, V. Porziella, V. Cardaci, P. Granone, et al. Farnesyltransferase Inhibitors and Human Malignant Pleural Mesothelioma: A First-Step Comparative Translational Study Clin. Cancer Res., March 1, 2005; 11(5): 2026 - 2037. [Abstract] [Full Text] [PDF]

				W. Weder, P. Kestenholz, C. Taverna, S. Bodis, D. Lardinois, M. Jerman, and R. A. Stahel Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma J. Clin. Oncol., September 1, 2004; 22(17): 3451 - 3457. [Abstract] [Full Text] [PDF]

				V.B. Antony, R. Loddenkemper, P. Astoul, C. Boutin, P. Goldstraw, J. Hott, F. Rodriguez Panadero, and S.A. Sahn Management of malignant pleural effusions Eur. Respir. J., August 1, 2001; 18(2): 402 - 419. [Full Text] [PDF]

				M. Odaka, D. H. Sterman, R. Wiewrodt, Y. Zhang, M. Kiefer, K. M. Amin, G.-P. Gao, J. M. Wilson, J. Barsoum, L. R. Kaiser, et al. Eradication of Intraperitoneal and Distant Tumor by Adenovirus-mediated Interferon-{beta} Gene Therapy Is Attributable to Induction of Systemic Immunity Cancer Res., August 1, 2001; 61(16): 6201 - 6212. [Abstract] [Full Text] [PDF]

				G. Maggi, C. Casadio, R. Cianci, O. Rena, and E. Ruffini Trimodality management of malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., March 1, 2001; 19(3): 346 - 350. [Abstract] [Full Text] [PDF]

				Management of Malignant Pleural Effusions Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1987 - 2001. [Full Text]

				V. W. Rusch and E. S. Venkatraman Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically Ann. Thorac. Surg., November 1, 1999; 68(5): 1799 - 1804. [Abstract] [Full Text] [PDF]

				D. H. Sterman, L. R. Kaiser, and S. M. Albelda Advances in the Treatment of Malignant Pleural Mesothelioma Chest, August 1, 1999; 116(2): 504 - 520. [Abstract] [Full Text] [PDF]

				V. W. Rusch and E. Venkatraman THE IMPORTANCE OF SURGICAL STAGING IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA J. Thorac. Cardiovasc. Surg., April 1, 1996; 111(4): 815 - 826. [Abstract] [Full Text]

				W. R. Smythe, H. C. Hwang, A. A. Elshami, K. M. Amin, S. M. Albelda, and L. R. Kaiser Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy J. Thorac. Cardiovasc. Surg., April 1, 1995; 109(4): 626 - 631. [Abstract] [Full Text]